37906-39-1

Usage

Uses

Used in Pharmaceutical Synthesis:
1-(3,4-Dichlorophenyl)-2-(1H-imidazol-1-yl)ethanone is used as a key intermediate in the synthesis of various pharmaceutical drugs. Its unique chemical structure allows for the development of new drug candidates with potential therapeutic applications.
Used in Research Applications:
1-(3,4-DICHLOROPHENYL)-2-(1H-IMIDAZOL-1-YL)ETHANONE serves as a valuable tool in chemical research, enabling scientists to explore its properties and potential interactions with biological systems. It is used to study the mechanisms of action and to develop new strategies for drug discovery.
Used in Antifungal and Antimicrobial Agents:
1-(3,4-Dichlorophenyl)-2-(1H-imidazol-1-yl)ethanone exhibits antifungal and antimicrobial properties, making it a potential candidate for the development of new agents to combat infections caused by fungi and bacteria.
Used in Enzyme Inhibition:
1-(3,4-DICHLOROPHENYL)-2-(1H-IMIDAZOL-1-YL)ETHANONE has been investigated as a potential inhibitor of certain enzymes, which could have implications in the treatment of various diseases and conditions. By targeting specific enzymes, it may contribute to the development of more effective therapies.
Used in Organic Synthesis:
1-(3,4-Dichlorophenyl)-2-(1H-imidazol-1-yl)ethanone also serves as a building block for the synthesis of other organic compounds, expanding its utility in the field of organic chemistry and potentially leading to the discovery of new materials and applications.

InChI:InChI=1/C11H8Cl2N2O/c12-9-2-1-8(5-10(9)13)11(16)6-15-4-3-14-7-15/h1-5,7H,6H2

Upstream product

• 60-29-7 diethyl ether 
• 2632-10-2 2-bromo-1-(3,4-dichlorophenyl)ethanone 
• 288-32-4 1H-imidazole 
• 2642-63-9 3',4'-dichloroacetophenone 

Downstream Products

• 1037732-88-9 VUF 10132 
• 27523-05-3 1-(3,4-dichlorophenyl)-2-(1H-imidazol-1-yl)ethan-1-ol 
• 119393-52-1 N-<1-(3,4-dichlorophenyl)-2-(1H-imidazol-1-yl)ethylidene>methanamine N-oxide 

Relevant academic research and scientific papers

Novel BuChE-IDO1 inhibitors from sertaconazole: Virtual screening, chemical optimization and molecular modeling studies

In our effort towards the identification of novel BuChE-IDO1 dual-targeted inhibitor for the treatment of Alzheimer's disease (AD), sertaconazole was identified through a combination of structure-based virtual screening followed by MM-GBSA rescoring. Preliminary chemical optimization was performed to develop more potent and selective sertaconazole analogues. In consideration of the selectivity and the inhibitory activity against target proteins, compounds 5c and 5d were selected for the next study. Further modification of compound 5c led to the generation of compound 10g with notably improved selectivity towards BuChE versus AChE. The present study provided us with a good starting point to further design potent and selective BuChE-IDO1 inhibitors, which may benefit the treatment of late stage AD.

BuChE-IDO1 inhibitor as well as preparation method and application thereof

The invention relates to the field of medicines, and particularly discloses a BuChE-IDO1 inhibitor as well as a preparation method and application thereof. The 7-chlorine-3-substituted benzothiophene part of sertaconazole is chemically modified, the influence of the 7-chlorine-3-substituted benzothiophene part of sertaconazole on the in-vitro inhibitory activity of AChE, BuChE and IDO1 is explored, the target compound is further optimized, and the technical problems that an existing BuChE-IDO1 inhibitor is poor in pertinence and safety are solved. What is explored is that an appropriate substituent group introduced to a 2-benzothiazole ring can form additional interaction with surrounding amino acids and heme iron, so that the binding affinity of the analogue with BuChE and IDO1 is increased, and a new idea is broadened for more efficient and targeted treatment of advanced AD diseases.

Mutant type IDH inhibitors, preparation method thereof, and pharmaceutical composition containg the same as an active ingredient

The present invention is a mutated IDH1 inhibitor. The present invention relates to a compound represented by chemical formula 1, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof according to the present invention, which has excellent inhibitory activity against mutated IDH1 and can reduce intracellular tumor-induced metabolite (2-HG), and a health functional food composition for preventing or IDH1 treating cancer, comprising the same as an active ingredient.

Diaryl-containing imidazole compound and preparation method and medical application thereof

The invention discloses a diaryl-containing imidazole compound. The invention further discloses application of the diaryl-containing imidazole compound to preparation of drugs for preventing or treating Alzheimer's disease. The inventor screens butyrylcholine esterase and IDO1 as carriers for inhibiting the activity to evaluate the effect of the diaryl imidazole compound to treat Alzheimer's disease, and finds that the diaryl imidazole compound has good in vitro activity, and can be further developed as a precursor substance for performing the Alzheimer's disease resistant effect by inhibitingthe activity of cholinesterase. (The formula is shown in the description).

Detailed analysis and follow-up studies of a high-throughput screening for indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors

Indoleamine 2,3-dioxygenase 1 (IDO1) is a key regulator of immune responses and therefore an important therapeutic target for the treatment of diseases that involve pathological immune escape, such as cancer. Here, we describe a robust and sensitive high-throughput screen (HTS) for IDO1 inhibitors using the Prestwick Chemical Library of 1200 FDA-approved drugs and the Maybridge HitFinder Collection of 14,000 small molecules. Of the 60 hits selected for follow-up studies, 14 displayed IC50 values below 20 μM under the secondary assay conditions, and 4 showed an activity in cellular tests. In view of the high attrition rate we used both experimental and computational techniques to identify and to characterize compounds inhibiting IDO1 through unspecific inhibition mechanisms such as chemical reactivity, redox cycling, or aggregation. One specific IDO1 inhibitor scaffold, the imidazole antifungal agents, was chosen for rational structure-based lead optimization, which led to more soluble and smaller compounds with micromolar activity.

Fungicidally active pyrazole compounds

The invention relates to new, fungicidally active pyrazole compounds of the general formula STR1 wherein Ar is an unsubstituted phenyl group or a phenyl group, substituted with 1 or 2 substituents selected from the group consisting of C1 -C4 alkyl, halogen, nitro, cyano and C1 -C4 alkoxy, or with 3 halogen atoms, R is a C1 -C12 alkyl group, R1 is a C1 -C4 alkyl group, and Y is CH or N. The invention also relates to new imidazolylvinyldithioacetals, suitable as starting materials for preparing said new pyrazole compounds and also having fungicidal activity.